Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron

Supportive Care in Cancer

Volumn 6, Issue 2, 1998, Pages 132-138

  Holdsworth, M T ^a   Raisch, D W ^b   Winter, S S ^c   Chavez, C M ^c  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b University of New Mexico   (United States)

^c Medical Center   (United States)

Author keywords

Intrathecal chemotherapy; Leukemia; Ondansetron; Pediatrics

Indexed keywords

CYTARABINE; HYDROCORTISONE; METHOTREXATE; ONDANSETRON;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANTIEMETIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; FEMALE; FOLLOW UP; HUMAN; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT OUTCOME; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYTARABINE; FEMALE; HUMANS; HYDROCORTISONE; INJECTIONS, SPINAL; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; METHOTREXATE; NAUSEA; ONDANSETRON; TREATMENT OUTCOME;

EID: 0031888072     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200050147     Document Type: Article

References (12)

1. Alvarez O, Freeman A, Bedros A, Call SK, Volsch J, Kalbermatter O, Halverson J, Convy L, Cook L, Mick K, Zimmerman G (1995) Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies. J Pediatr Hematol Oncol 17:145-150
2. Barnes JM, Barnes NM, Costall B, et al (1990) Identification and distribution of 5-HT3 recognition sites within the human brainstem. Neurosci Lett 111:80-86
3. Billett AL, Sallan SE (1994) Antiemetics in children receiving cancer chemotherapy. Support Care Cancer 2:279-285
4. Craig JB, Powell BL (1987) Review: the management of nausea and vomiting in clinical oncology. Am J Med Sci 293:34-44
5. Hesketh PJ, Beck T, Uhlenhopp M, Dris MG, Hainsworth JD, Harker WG, Cohen JR, Lester E, Kessler JF, Griffen D, Rouse P (1995) Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen. J Clin Oncol 13:2117-2122
6. 3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br J Pharmacol 97:247-255
7. Holdsworth MT, Raisch DW, Duncan MH, Chavez CM, Leasure MM (1995) Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia. Ann Pharmacother 29:16-21
8. Ross BK, Chadwick HS, Mancuso JJ, Benedetti C (1992) Sprotte needle for obstetric anesthesia: decreased incidence of post durai puncture headache. Reg Anesth 17:29-33
9. Seynaeve C, Schuller J, Buser K, Porteder H, Van Belle S, Sevelda P, Christmann D, Schmidt M, Kitchener H, Paes D, Mulder PHM de (1992) Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multi-centre, double-blind, randomised, parallel group study. Br J Cancer 66:192-197
10. Smith WL, Callaham EM, Alphin RS (1988) The emetic activity of centrally administered cisplatin in cats and its antagonism by zacopride. J Pharm Pharmacol 40:142-143
11. Tortorice PV, O'Connell MB (1990) Management of chemotherapy-induced nausea and vomiting. Pharmacotherapy 10:129-145
12. Zeltzer LK, LeBaron S, Zeltzer PM (1984) A prospective assessment of chemotherapy-related nausea and vomiting in children with cancer. Am J Pediatr Hematol Oncol 6:5-16